Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Defence Therapeutics Inc. Stock

Price
Target price
€0.38

€0.38

-3.860%
-0.015
-3.860%
-
 
20.02.26 / Tradegate WKN: A3CN14 / Name: Defence Therapeutics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Defence Therapeutics Inc. in the next few years
Wizard

Defence Therapeutics Inc. Stock

Heavy losses for Defence Therapeutics Inc. today as the stock fell by -€0.015 (-3.860%).
Our community identified positive and negative aspects for Defence Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Defence Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
What does Defence Therapeutics Inc. do?

Pros and Cons of Defence Therapeutics Inc. in the next few years

Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-09

Defence Therapeutics Inc. scheint eine solide finanzielle Leistung zu verzeichnen, gemessen an den vorgelegten Jahresbilanzen. Bei der Analyse der Vermögens-, Cashflow- und Einkommenszahlen wird allerdings klar, dass das Unternehmen trotz offensichtlicher Fortschritte auch einige Herausforderungen zu bewältigen hat.

Die Bilanzen zeigen insgesamt eine beeindruckende Wachstumsdynamik in Bezug auf die Gesamtaktiva von Defence Therapeutics. Von 2020 bis 2022 hat das Unternehmen seinen Wert fast vervierfacht, was auf solides Management und erfolgreiches Wachstum schließen lässt.

Des Weiteren ist der hohe Cashflow besonders erwähnenswert. Im Jahr 2021 verzeichnete das Unternehmen einen positiven Cashflow, der eine robuste finanzielle Gesundheit und Liquidität signalisiert. Eine solide Cash-Position versetzt ein Unternehmen in die Lage, seine kurzfristigen Verbindlichkeiten zu bedienen, zu investieren und eventuelle finanzielle Engpässe besser zu bewältigen.

Show more
Register To Post

News

Defence Therapeutics Aligns Accum ADC Strategy through Multidisciplinary Scientific Advisory Board
Defence Therapeutics Aligns Accum ADC Strategy through Multidisciplinary Scientific Advisory Board

Montreal, QC, Canada, February 10th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, reported

irwpresse_en 
0 10.02.26
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

Montreal, QC, Canada, February 4th, 2026 – Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today

irwpresse_en 
0 04.02.26
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate its Proprietary Radiopharmaceutical Pipeline
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate its Proprietary Radiopharmaceutical Pipeline

Montreal, QC, Canada, January 28th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today

irwpresse_en 
0 29.01.26